Brawnpharma

Delhi, India Founded: 1985 • Age: 41 yrs Listed
Pharmaceutical products are developed and distributed by Brawnpharma.

About Brawnpharma

Brawnpharma is a publicly listed company based in Delhi (India) founded in 1985. Pharmaceutical products are developed and distributed by Brawnpharma. Its Indian entity Brawn Biotech Limited reported revenue of β‚Ή17.43 Cr.

Company details

Brawnpharma was established in 1985 in Delhi, India, within the pharmaceutical sector. Operations are centered on the development, manufacturing, and distribution of medicinal products. Services include formulation and supply to healthcare markets. The company is headquartered in Delhi, with activities spanning the Indian pharmaceutical industry. Limited public details are available regarding specific product lines or expansions.

Key Metrics
  • Market Cap
    ₹6.30 Cr

    BRAWN · BSE

  • Share Price
    ₹20.99

    -0.05% today

  • Revenue
    ₹16.98 Cr

    FY 2025-26 · +26.2% YoY

  • EBITDA
    −₹0.31 Cr

    Margin -1.8%

  • Net Profit
    ₹0.96 Cr

    FY 2025-26 · +155.2% YoY

  • P/E (TTM)
    31.4x

    P/B 2.0x

  • ROE
    22.2%

    ROCE 0.0%

Board of directors of Brawn Biotech Limited (Brawnpharma)

Brawn Biotech Limited is the primary company behind Brawnpharma. The board of Brawn Biotech Limited currently have 3 directors; the longest-serving is Brij Raj Gupta, appointed in 1985. 19 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Brij Raj Gupta
DIN 00974969
Director07 Nov 198541 yrsBrawn Biotech Limited
Mayank Jain
DIN 07993851
Director27 Aug 20242 yrs 2 moBrawn Biotech Limited
Pooja Jha
DIN 10749145
Director27 Aug 20242 yrs 2 moBrawn Biotech Limited

IPO & Listings of Brawnpharma

Brawnpharma is a publicly listed company on the BSE with ticker symbol BRAWN in India, operating in the Pharmaceuticals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onBSE: BRAWN
  • Listed entityBrawn Biotech Limited
  • Exchange sectorPharmaceuticals

Financials of Brawnpharma

Exchange-reported figures of Brawn Biotech Limited, the listed company behind Brawnpharma (BSE: BRAWN).

Financial Highlights

FY 2025-26 Β· Standalone
Revenue
₹16.98 Cr
+26.2% YoY
EBITDA
−₹0.31 Cr
+82.6% YoY
Profit After Tax
₹0.96 Cr
+155.2% YoY
Net Worth
₹4.34 Cr
+29.2% YoY
Total Assets
₹5.69 Cr
-49.0% YoY
Total Debt
Nil

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue16.9813.4616.4922.238.6234.9849.62
Revenue growth+26.2%-18.4%-25.8%+157.9%-75.4%-29.5%-
EBITDA(0.31)(1.78)(1.47)(0.29)(2.00)(0.59)0.74
EBITDA margin-1.8%-13.2%-8.9%-1.3%-23.2%-1.7%+1.5%
Profit before tax0.02(1.80)(1.54)(0.40)(2.11)(0.35)0.83
Net profit0.96(1.74)(1.23)(0.85)(1.64)(0.55)0.60
Net profit margin+5.7%-12.9%-7.5%-3.8%-19.0%-1.6%+1.2%
EPS (β‚Ή)3.14(5.80)(4.16)(2.89)(5.48)(1.84)1.97
Balance sheet
Total assets5.6911.168.086.487.468.979.37
Net worth4.343.365.066.317.228.799.26
Total debt0.000.000.000.000.000.000.00
Cash & bank0.280.200.400.440.220.400.40
Net working capital1.958.186.635.355.867.838.29
Cash flow
Cash from operations0.770.05(0.03)0.320.190.03(0.08)
Cash from investing(0.03)(0.24)(0.01)(0.10)(0.30)0.00(0.02)
Cash from financing0.000.000.00(0.01)(0.06)(0.04)(0.05)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue5.626.081.984.314.895.802.263.84
Revenue growth (YoY)+14.9%+4.8%-12.4%+12.2%+48.2%+42.9%--
Other income0.140.140.180.090.090.090.090.00
Total expenses5.706.032.484.324.885.622.814.25
EBITDA(0.08)0.05(0.50)(0.01)0.010.18(0.55)(0.41)
EBITDA margin-1.4%+0.8%-25.3%-0.2%+0.2%+3.1%-24.3%-10.7%
Depreciation0.030.030.030.030.030.030.030.03
Interest0.000.000.000.000.000.000.000.00
Profit before tax0.030.16(0.35)0.050.070.24(0.49)(0.44)
Tax0.000.00(0.94)0.000.000.000.000.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 19 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue5.626.081.984.314.895.802.263.84
Revenue growth (YoY)+14.9%+4.8%-12.4%+12.2%+48.2%+42.9%--
Other income0.140.140.180.090.090.090.090.00
Total expenses5.706.032.484.324.885.622.814.25
EBITDA(0.08)0.05(0.50)(0.01)0.010.18(0.55)(0.41)
EBITDA margin-1.4%+0.8%-25.3%-0.2%+0.2%+3.1%-24.3%-10.7%
Depreciation0.030.030.030.030.030.030.030.03
Interest0.000.000.000.000.000.000.000.00
Profit before tax0.030.16(0.35)0.050.070.24(0.49)(0.44)
Tax0.000.00(0.94)0.000.000.000.000.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue16.9813.4616.4922.238.6234.9849.62
Revenue growth+26.2%-18.4%-25.8%+157.9%-75.4%-29.5%-
Other income0.450.090.090.010.000.310.17
Total expenses17.2915.2417.9622.5210.6235.5748.88
Employee cost0.681.131.401.401.802.363.08
EBITDA(0.31)(1.78)(1.47)(0.29)(2.00)(0.59)0.74
EBITDA margin-1.8%-13.2%-8.9%-1.3%-23.2%-1.7%+1.5%
Depreciation0.120.110.100.110.050.030.03
Interest0.000.000.060.010.060.040.05
Profit before tax0.02(1.80)(1.54)(0.40)(2.11)(0.35)0.83
Tax(0.94)(0.06)(0.30)0.45(0.47)0.200.23
Net profit0.96(1.74)(1.23)(0.85)(1.64)(0.55)0.60
Net profit margin+5.7%-12.9%-7.5%-3.8%-19.0%-1.6%+1.2%
EPS (β‚Ή)3.14(5.80)(4.16)(2.89)(5.48)(1.84)1.97
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital3.003.003.003.003.003.003.00
Reserves & surplus1.340.362.063.314.225.796.26
Shareholders' funds (net worth)4.343.365.066.317.228.799.26
Secured loans0.000.000.000.000.000.000.00
Unsecured loans0.000.000.000.000.000.000.00
Total debt0.000.000.000.000.000.000.00
Total liabilities5.6911.168.086.487.468.979.37
Assets
Gross block1.051.020.780.770.670.380.38
Net block0.360.460.330.370.380.140.18
Capital work in progress0.000.000.000.000.000.000.00
Investments0.000.000.000.000.000.000.00
Inventories10.0610.476.024.794.720.260.39
Sundry debtors3.553.413.885.322.819.2815.00
Cash & bank balances0.280.200.400.440.220.400.40
Loans & advances3.233.432.842.854.432.793.42
Total current assets17.1217.5113.1413.4012.1812.7319.21
Total current liabilities15.179.336.518.056.324.9010.92
Net working capital1.958.186.635.355.867.838.29
Total assets5.6911.168.086.487.468.979.37
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.200.000.440.220.400.400.54
Net cash from operating activities0.770.05(0.03)0.320.190.03(0.08)
Net cash from investing activities(0.03)(0.24)(0.01)(0.10)(0.30)0.00(0.02)
Net cash from financing activities0.000.000.00(0.01)(0.06)(0.04)(0.05)
Net change in cash0.74(0.20)(0.04)0.21(0.17)0.00(0.14)
Closing cash0.280.200.400.440.220.400.40
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+26.2%-18.4%-25.8%+157.9%-75.4%-29.5%-
EBITDA growth+82.6%-21.1%-406.9%+85.5%-239.0%-179.7%-
PBT growth+9998.0%-16.9%-285.0%+81.0%-502.9%--54.4%
Net income growth+155.2%-41.5%-44.7%+48.2%-198.2%-191.7%-
Revenue CAGR (3Y)-8.6%+16.0%-22.2%-23.5%-49.1%-14.4%-6.4%
EBITDA CAGR (3Y)+2.3%-3.8%+35.6%----15.6%
Profitability & leverage
Net income margin+5.7%-12.9%-7.5%-3.8%-19.0%-1.6%+1.2%
Return on capital employed0.0%0.0%-20.5%-5.7%-25.0%-3.5%+9.6%
Return on net worth+22.2%0.0%-22.0%-12.9%-20.5%-6.1%+6.6%
Debt / equity0.000.000.000.000.000.000.00
Long-term debt / equity0.000.000.000.000.000.000.00
Interest cover0.000.00-3.82-2.50-2.93-6.457.04
Efficiency & per share
Fixed asset turnover16.4114.9621.2830.8816.4292.05132.32
Inventory turnover1.651.633.054.683.46107.63135.95
Debtors turnover4.883.693.585.471.432.883.15
EPS (β‚Ή)3.14(5.80)(4.16)(2.89)(5.48)(1.84)1.97
Dividend per share (β‚Ή)0.000.000.000.000.000.000.00
Book value per share (β‚Ή)14.4611.2116.8821.0324.0729.3130.87
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Brawnpharma

Premium access

Complete news archive for Brawnpharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Brawnpharma

Brawnpharma was founded in 1985.

Brawnpharma is headquartered in Delhi, India. It is registered at Delhi, Delhi, India.

The primary company behind Brawnpharma, Brawn Biotech Limited, reported revenue of β‚Ή17.43 Cr for FY 2026, up 26% year on year.

Brawnpharma was established in 1985 in Delhi, India, within the pharmaceutical sector. Operations are centered on the development, manufacturing, and distribution of medicinal products. Services include formulation and supply to healthcare markets. The company is headquartered in Delhi, with activities spanning the Indian pharmaceutical industry. Limited public details are available regarding specific product lines or expansions.

Yes, Brawnpharma is publicly traded on BSE under the ticker symbol BRAWN.

Brawnpharma operates through Brawn Biotech Limited.

The legal entities of Brawnpharma currently have 5 directors, including Brij Raj Gupta, Priyanka Sharma, Mayank Jain and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available